A major barrier to HIV eradication is the existence of a small pool of long-lived latently-infected, resting memory CD4[+] T cells carrying an integrated form of the viral genome. Memory T cells encompass a variety of cell subsets all endowed with specific survival and differentiation properties. We have recently demonstrated that the privileged cell type where HIV establishes its resen/oir is the central memory T cell (T{CM}) and its immediate progeny, the transitional memory T cell (T{TM})- IL-7 is one of the cytokines that is responsible for sustaining low levels of proliferation in T{CM} and T{TM}. Harnessing IL-7 interactions with its receptor on TCM could provide a strategy to prevent the survival and proliferation of these cells, and to prevent the persistence of the HIV reservoir. Another cytokine known to play a major role in memory T cell survival is IL-15. We have recently demonstrated that IL-15 engagement with its receptor on resting CD4[+] T{CM} that harbor latent virus will induce their differentiation into short-lived effector memory T cells (T{EM}) that can proliferate and produce virus. We propose to exploit this capacity of IL-15 so that the pool of resting, infected T{CM} cells can be depleted in vitro and in vivo. We will first determine the relative impact of IL-7 and IL-15 on HIV persistence in vivo and in vitro by measuring the contribution of these cytokines to the maintenance of the pool of latently infected cells in blood and tissues obtained from subjects receiving suppressive ART and by evaluating their capacity to induce viral reactivation (Specific Aim 1). We will then test the hypothesis that blocking the IL-7 pathway or, conversely, administrating IL-15 to optimally-treated macaquess could be used as strategies to deplete the latent viral reservoir (Specific Aim 2). Our proposed interventions target the major cellular source of persistent virus during treatment, and although they may not work alone in eradicating HIV, they could complement other interventions by transiently reversing the host factors that are critical in maintaining latently infected cells.

Public Health Relevance

Eradication of HIV has been the focus of several clinical interventions that unfortunately have failed to reach their goal. Most of these strategies have relied on the use of complex antiviral regimens to test the hypothesis that eradication of HIV can be achieved by inhibiting the residual viral replication in CD4[+] T cells or in other compartments. In this project, we will focus on those host factors that contribute to maintanece of latency and which could be reversed using targeted therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI096109-02
Application #
8376028
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
2
Fiscal Year
2012
Total Cost
$580,362
Indirect Cost
$96,578
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Kumar, Nitasha A; van der Sluis, Renee M; Mota, Talia et al. (2018) Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4+ T Cells. J Immunol 201:1468-1477
Walters, Lucy C; Harlos, Karl; Brackenridge, Simon et al. (2018) Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nat Commun 9:3137
Adland, Emily; Hill, Matilda; Lavandier, Nora et al. (2018) Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. J Virol 92:
Boyer, Zoe; Palmer, Sarah (2018) Targeting Immune Checkpoint Molecules to Eliminate Latent HIV. Front Immunol 9:2339
Wang, Chia-Ching; Thanh, Cassandra; Gibson, Erica A et al. (2018) Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. Blood Adv 2:3479-3482
Reeves, Daniel B; Duke, Elizabeth R; Wagner, Thor A et al. (2018) A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nat Commun 9:4811
Rezaei, Simin D; Lu, Hao K; Chang, J Judy et al. (2018) The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed. J Virol 92:
Evans, Vanessa A; van der Sluis, Renée M; Solomon, Ajantha et al. (2018) Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. AIDS 32:1491-1497
Kiniry, Brenna E; Li, Shengbin; Ganesh, Anupama et al. (2018) Detection of HIV-1-specific gastrointestinal tissue resident CD8+ T-cells in chronic infection. Mucosal Immunol 11:909-920
Burbelo, Peter D; Price, Richard W; Hagberg, Lars et al. (2018) Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir? J Infect Dis 217:1024-1032

Showing the most recent 10 out of 190 publications